Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian G Feagan

Showing results (11-20 of 464) with videos related to

Pageof 47
Sort By:
The Lancet. Gastroenterology & Hepatology|October 26, 2019
Global burden of inflammatory bowel diseaseVipul Jairath, Brian G Feagan
Expert Opinion on Drug Safety|March 31, 2015
Safety of infliximab for the treatment of inflammatory bowel disease: current understanding of the potential for serious adverse eventsReena Khanna, Brian G Feagan
Gastroenterology Clinics of North America|June 5, 2004
Methotrexate in inflammatory bowel diseaseBrian G Feagan, Ahmad Alfadhli
Gastroenterology|March 2, 2016
ReplyReena Khanna, Brian G Feagan,
Current Treatment Options in Gastroenterology|January 8, 2014
Current and Future Status of Therapeutic Drug Monitoring in the Treatment of IBDReena Khanna, Brian G Feagan
Reviews in Gastroenterological Disorders|December 13, 2002
Initial therapy for mild to moderate Crohn's disease: mesalamine or budesonide?Brian G Feagan, William J Sandborn
Gastroenterology|September 14, 2004
The efficacy of azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in patients with Crohn's disease remains uncertainWilliam J Sandborn, Brian G Feagan
Expert Opinion on Biological Therapy|July 28, 2015
Combination therapy for the treatment of Crohn's diseaseMahmoud H Mosli, Brian G Feagan
Inflammatory Bowel Diseases|May 31, 2012
Once daily oral mesalamine compared to conventional dosing for induction and maintenance of remission in ulcerative colitis: a systematic review and meta-analysisBrian G Feagan, John K MacDonald
Gastroenterology|October 8, 2016
ReplyMiguel D Regueiro, Brian G Feagan
Pageof 47

Showing results (11-20 of 464) with videos related to

Sort By:
Pageof 47
The Lancet. Gastroenterology & Hepatology|October 26, 2019
Global burden of inflammatory bowel diseaseVipul Jairath, Brian G Feagan
Expert Opinion on Drug Safety|March 31, 2015
Safety of infliximab for the treatment of inflammatory bowel disease: current understanding of the potential for serious adverse eventsReena Khanna, Brian G Feagan
Gastroenterology Clinics of North America|June 5, 2004
Methotrexate in inflammatory bowel diseaseBrian G Feagan, Ahmad Alfadhli
Gastroenterology|March 2, 2016
ReplyReena Khanna, Brian G Feagan,
Current Treatment Options in Gastroenterology|January 8, 2014
Current and Future Status of Therapeutic Drug Monitoring in the Treatment of IBDReena Khanna, Brian G Feagan
Reviews in Gastroenterological Disorders|December 13, 2002
Initial therapy for mild to moderate Crohn's disease: mesalamine or budesonide?Brian G Feagan, William J Sandborn
Gastroenterology|September 14, 2004
The efficacy of azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in patients with Crohn's disease remains uncertainWilliam J Sandborn, Brian G Feagan
Expert Opinion on Biological Therapy|July 28, 2015
Combination therapy for the treatment of Crohn's diseaseMahmoud H Mosli, Brian G Feagan
Inflammatory Bowel Diseases|May 31, 2012
Once daily oral mesalamine compared to conventional dosing for induction and maintenance of remission in ulcerative colitis: a systematic review and meta-analysisBrian G Feagan, John K MacDonald
Gastroenterology|October 8, 2016
ReplyMiguel D Regueiro, Brian G Feagan
Pageof 47